No comments have been submitted
|March 14, 2010: Safety and Efficacy of Adjusted-Dose Eptifibatide in Patients With Acute Coronary Syndromes and Reduced Renal Function
At ACC 2010, Dr. Chiara Melloni presents: Safety and Efficacy of Adjusted-Dose
Eptifibatide in Patients With Acute Coronary Syndromes and Reduced Renal Function.
Disclosures at the time of filming:
- Chiara Melloni: None.
- Stefan K. James: Research grants and speaker fees received from Astra Zeneca, Sanofi
Aventis, BMS, Eli Lilly, and Schering Plough.
- Jennifer A. White: None.
- Robert P. Giugliano: Research grant support, advisory board, and honoraria for lectures,
Schering-Plough, Inc., and Merck & Co., Inc.
- Robert A. Harrington: Research funding and consulting with Schering-Plough, now Merck. A
complete listing of Dr. Harrington’s relationships with industry is available at
- Kurt Huber: Research grants from Bristol-Myers Squibb, Eli Lilly, Medtronic,
Sanofi-Aventis; consulting fees from AstraZeneca, Bayer, Boehringer-Ingelheim,
Bristol-Myers Squibb, Daiichi Sankyo, Fibrex, Eli Lilly, Portola, Sanofi-Aventis,
Schering-Plough, The Medicines Company, and Schering Plough; lecture fees from
AstraZeneca, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cordis /
Johnson&Johnson, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Pfizer, and
- Pierluigi Tricoci: Research grant and advisory board, Merck & Co., Inc.
- Paul W. Armstrong: Consulting or other services that generate personal income from
sanofi-aventis, Bristol-Myers Squibb Canada, Merck Frosst Canada Ltd, Abbott Laboratories,
GlaxoSmithKline, Bristol-Myers Squibb/Pfizer, Regado Biosciences, and F. Hoffmann-La Roche
Ltd; research grant or contract from Boehringer Ingelheim (Canada) Ltd, sanofi-aventis
Canada, Eli Lilly, Schering-Plough Research Institute, Scios Inc/Ortho-Biotech,
GlaxoSmithKline, Portola Pharmaceutical Inc, Uppsala Clinical Research Center and
AstraZeneca, and Merck & Company Inc., that partially supports his university salary
and/or research projects.
- Frans Van de Werf: Research grants from Schering-Plough (now Merck) and Roche; advisory
board and speakers fee from Schering-Plough, Merck, and Roche.
- Gilles Montalescot: Research support from Schering-Plough, Inc., and Merck & Co.,
- Robert M. Califf: Research funding and consulting with Schering-Plough, now Merck (all
consulting funds donated to not for profits). A complete listing of Dr. Califf’s
relationships with industry is available at http://www.dcri.duke.edu/research/coi.jsp.
- L. Kristin Newby: Research grant from Schering Plough and Merck & Co., Inc. through
the DCRI; consulting honoraria from Schering-Plough. A complete listing of Dr. Newby’s
relationships with industry is available at www.dcri.duke.edu/research/coi.jsp.
[ Download video ]